Lantern Pharma Inc. — Form 8-K

Lantern Pharma (market cap ~$33.9M) separated Open Medicine AI (OMAI) as a wholly-owned subsidiary with executed commercial licenses; OMAI intends to raise outside capital and eventually list publicly. LP-300 HARMONIC trial showed median 8.9-month progression-free survival in 9 EGFR L858R patients completing 6 cycles (vs. 8.4 months across 16 total L858R patients, hazard ratio 0.37); FDA approved protocol amendments to focus enrollment on L858R patients and extend treatment from 6 to 8 cycles. LP-184 gained EMA clearance for Phase 1b/2 bladder cancer trial at Rigshospitalet, Denmark, and FDA cleared TNBC trial initiation. Cash position: $7.4M as of June 30, 2026 (down from $10.1M Dec 31, 2025); Q2 operating loss decreased 25% YoY to $3.5M; net loss $7.1M (Q2) including $3.6M non-cash warrant expense.